Close
Close

Functional Human Antibody Discovery Service by Premade Library

Screening Services Workflow Premade Libraries Cases Related Services Why Choose Us? FAQ

Navigating the path to a therapeutic antibody can be fraught with challenges: protracted timelines, difficult-to-drug targets, and candidates that fail late in development due to poor biophysical properties. Creative Biolabs' integrated service leverages our world-class, pre-validated human antibody libraries and advanced screening platforms to de-risk your discovery program. We deliver functionally active, high-affinity antibody candidates with superior developability profiles, compressing your discovery timeline from months to weeks.

Request Your Quote Today

Overcome Discovery Deadlocks with Our Screening Platform: Precision, Speed, and Strategy

From Vast Diversity to Functional Candidate, Faster Than Ever.

At Creative Biolabs, screening is a designed strategy, not a routine process. We go beyond finding binders to isolate molecules that mirror your specific Mechanism of Action (MoA).

Fig.1 Diverse Platforms. (Creative Biolabs AI)

Diverse Platforms
Proprietary Phage and Yeast display platforms.
Fig.2 Customized Panning. (Creative Biolabs AI)

Customized Panning
Multi-parameter strategies to eliminate sticky binders and enrich for high-specificity hits.
Fig.3 Target Flexibility. (Creative Biolabs AI)

Target Flexibility
Expertise in soluble proteins, peptides, and complex cell-surface antigens (i.e., GPCRs, Ion Channels).

Workflow

  • Fig.4 Strategic Design & Target QC. (Creative Biolabs AI)
    Strategic Design & Target QC

    Collaborative project goals consultation.

    Antigen expression, purification, and rigorous QC (e.g., SDS-PAGE, SEC-HPLC).

    Deliverables

    Project-specific screening plan

    QC-validated antigen

  • Fig.5 Biopanning & Enrichment. (Creative Biolabs AI)
    Biopanning & Enrichment

    Up to 5 rounds of competitive and subtractive panning against target antigens.

    Progressive stringency (e.g., lower antigen concentration, longer washing) and off-target depletion to enrich highly specific binders.

    Deliverables

    Enriched phage/yeast population pool.

  • Fig.6 High-Throughput Hit ID & Screening. (Creative Biolabs AI)
    High-Throughput Hit ID & Screening

    High-throughput screening (ELISA/FACS) of hundreds of individual clones.

    Hit confirmation and prioritization based on signal and/or preliminary functional readouts.

    Deliverables

    List of confirmed positive binders.

    Primary screening data report.

  • Fig.7 In-depth Functional Characterization. (Creative Biolabs AI)
    In-depth Functional Characterization

    Expression and purification of candidates (e.g., scFv-Fc, Fab).

    Affinity ranking (ELISA, FACS, SPR) and target-specific functional assays (e.g., cell-based neutralization, receptor blocking assays).

    Deliverables

    Purified antibody candidates.

    Comprehensive characterization report with affinity data & functional assay results.

    Unique antibody sequences.

Discuss Your Screening Strategy with an Expert

Ready-to-Screen Antibody Libraries

Our premade human and humanized antibody libraries combine high functional diversity with proven human germline frameworks to minimize liabilities and maximize hit quality.

Human Humanized VHH
Antibody Library ID Display Technology Library Format Library Size
HuScL-6
✅Highly Recommended 		pIII-fusion, Phagemid Phage Display Naïve scFv 2.1×1011
HuScL-3S pIII-fusion, Phagemid Phage Display Semi-synthetic scFv >1.0×1011
HuFabL-4 pIII-fusion, Phagemid Phage Display Naïve Fab 1.9×1010
HuFabssL-1 pIII-fusion, Phagemid Phage Display Naïve & synthetic Fab 1.8×1010

Find the Perfect Library for Your Target

Featured Case Studies: Delivering High-Value Functional Antibodies

How we solve the industry's most demanding antibody challenges.

Our service provides a high-efficiency gateway to therapeutic-grade antibodies. We specialize in navigating the difficult zones of antibody discovery, where standard platforms often fail, by delivering precision-engineered molecules tailored to specific functional requirements.

Functional Antagonism / Ligand-Blocking Antagonists
Fig.8 Ligand-Blocking Antagonists. (Creative Biolabs Original)
The Problem We Solve Traditional screening often identifies binders that fail to inhibit biological pathways or displace natural ligands.
Our Value Proposition Target-directed competitive screening to prioritize clones that bind the exact functional pocket.
Client Value: Direct discovery of potent inhibitors that move beyond binding to achieve true therapeutic antagonism.
ADC-Ready Internalization / Receptor-Mediated Uptake
Fig.9 Receptor-Mediated Uptake. (Creative Biolabs Original)
The Problem We Solve For ADCs, binding is insufficient; antibodies must trigger cellular entry to deliver payloads.
Our Value Proposition Functional cell-based screening to isolate leads that trigger receptor-mediated endocytosis.
Client Value: Optimized candidates for next-generation drug conjugates with confirmed intracellular delivery.
High-Resolution Specificity / Single Amino Acid Resolution
Fig.10 Single Amino Acid Resolution. (Creative Biolabs Original)
The Problem We Solve High cross-reactivity risks when targeting Neoantigens or mutations with only a single amino acid difference from Wild-Type.
Our Value Proposition High-stringency competitive selection designed to shave away all cross-reactive clones.
Client Value: 100% specificity for mutant targets, ensuring high safety profiles for TCR-like and precision therapies.
Translational Bridge / Multi-Species Cross-Reactivity
Fig.11 Multi-Species Cross-Reactivity. (Creative Biolabs Original)
The Problem We Solve Restarting discovery for different species (Mouse/NHP) causes significant preclinical delays.
Our Value Proposition Alternating species-specific biopanning to identify conserved epitopes across targets.
Client Value: A single lead candidate that works across all species, drastically reducing preclinical timelines.
Precision Tools for Clinical Bioanalysis / Anti-Idiotype Specificity
Type 1 Anti-Idiotype Antibody (Neutralizing) Type 2 Anti-Idiotype Antibody (Non-Neutralizing)
Fig.12 Type 1 Anti-Idiotype Antibody. (Creative Biolabs Original) Fig.13 Type 2 anti-idiotype antibody. (Creative Biolabs Original)
Mimic the target antigen, blocking the original antibody's activity. Bind without affecting the antibody's ability to bind its antigen.
Fig.14 Type 1 anti-idiotype antibody result. (Creative Biolabs Original) Fig.15 Type 2 anti-idiotype antibody result. (Creative Biolabs Original)
The Problem We Solve Distinguishing between active drug molecules and total drug concentration in complex serum.
Our Value Proposition Strategic segregation of Type 1 (Neutralizing) and Type 2 (Non-Neutralizing) binders within a single discovery cycle.
Client Value: Delivery of dual-purpose reagents that accelerate clinical bioanalysis and mechanistic studies.

Submit the Request for Quote

Related Services

Find additional antibody discovery services tailored to your specific needs.

Fig.16 Anti-peptide/protein antibody discovery. (Creative Biolabs AI)

Anti-Peptide/Protein Antibody Discovery

Fig.17 Anti-Cell-based target antibody discovery. (Creative Biolabs AI)

Anti-Cell-based Target Antibody Discovery

Fig.18 Bi-functional antibody discovery. (Creative Biolabs AI)

Bi-functional Antibody Discovery

Fig.19 Cell-internalizing antibody discovery. (Creative Biolabs AI)

Cell-Internalizing Antibody Discovery

Fig.20 Anti-epitope antibody discovery. (Creative Biolabs AI)

Anti-Epitope Antibody Discovery

Fig.21 Antibody discovery for immunotherapy. (Creative Biolabs AI)

Antibody Discovery for Immunotherapy

Fig.22 Anti-disease-specific target antibody discovery. (Creative Biolabs AI)

Anti-Disease-Specific Target Antibody Discovery

Have More Questions? Schedule a Technical Call

Why Industry Leaders Partner with Creative Biolabs?

Our Core Value Pillars

Maximized Discovery Success

Maximized Discovery Success
With library diversities reaching up to 1012, we ensure broad epitope coverage, allowing us to isolate rare, high-value functional antibodies that smaller libraries often miss.

Functional-First Approach

Functional-First Approach
Mechanism of action assays are integrated early into our workflow. We deliver candidates that are not just binders, but biologically active leads validated for your specific therapeutic goal.

De-risk Downstream Development

De-risk Downstream Development
Our antibodies are built on clinically validated human frameworks. By selecting superior biophysical properties early, we minimize future immunogenicity and manufacturing liabilities.

Accelerated Clinical Velocity

Accelerated Clinical Velocity
Our optimized, high-throughput workflows compress the discovery timeline. Move from target inception to validated hits in as little as 8-12 weeks.

Seamless Hit-to-Lead Platform

Seamless Hit-to-Lead Platform
We provide a true one-stop solution. From the initial hit, we offer integrated affinity maturation and reformatting into IgG, bispecific, CAR-T, or ADC.

The Platform Advantage: Turning Complexity into Certainty

Our technical capabilities are designed to meet the rigorous demands of the global pharmaceutical industry.

Our Technical Capability Your Strategic Advantage
Bespoke Strategy
  • Custom-designed selection pressures for every project.
  • No "one-size-fits-all"; we solve for your specific TPP.
Vast Diversity
  • Proprietary libraries with >1011 unique clones.
  • Discovery of rare, high-affinity hits missed by others.
NGS-Driven
  • Deep repertoire analysis for every selection round.
  • Data-backed confidence in lead selection and diversity.
Ready-to-Use
  • From library "hit" to validated, purified sequences.
  • Accelerated "Gene-to-Lead" velocity for your pipeline.

Customize Your Package - Get Pricing

Ready to move fast? Creative Biolabs will scope your target, advise on best library and protocol, and get screening up and running as soon as possible.

FAQ

  1. What is the typical timeline for a screening project?

    A typical project runs 6-12 weeks from panning to ranked hits, and 4-6 additional weeks for IgG reformatting and developability profiling. Affinity maturation, if required, adds 4-6 weeks.

  2. What information do I need to provide to start?

    Please share target details (sequence, format, tags), desired MoA/epitope, acceptable species cross-reactivity, available assays, counter-antigens, and any developability constraints (isotype, Fc). If cell-based, provide cell lines and expression context. To begin with, we require details about your target protein (sequence, known biology) and the desired functional outcome of the antibody (e.g., blocker, agonist). For most projects, you can either provide purified antigen, or we can express and purify it as part of the service.

  3. Which targets are supported?

    Soluble proteins, peptides, multiple transmembrane proteins (GPCRs, ion channels, transporters), complex receptors, PTM-specific epitopes, and native antigens presented on living cells or membranes.

  4. How many leads can I expect?

    Most campaigns deliver dozens of unique sequence validated binders; for function-first programs, we typically advance 5-15 prioritized, scFc/Fab/IgG formatted binders with binding and functional data.

  5. What antibody formats can you deliver?

    We can deliver sequences for scFv and Fab formats directly from the library. We also routinely reformat these hits into full-length IgG, bispecific, or other formats as a seamless downstream service to support your program's needs.

  6. Who owns the IP?

    You own the antibody sequences, data, and resultant inventions from your project. Creative Biolabs retains background IP and library construction IP.


All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Related Sections
Online Inquiry
CONTACT US
USA:
Europe:
Germany:
Call us at:
USA:
UK:
Germany:
Fax:
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us
© 2026 Creative Biolabs. | Contact Us